![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 735.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMGWP
RNS Number : 6658N
GW Pharmaceuticals PLC
30 July 2014
GW Pharmaceuticals to Report Q3 2014 Financial Results and Host Conference Call
on 6 August, 2014
London, UK, 30 July 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 6 August, 2014 its third quarter financial results for the period ending 30 June, 2014. GW will also host a conference call the same day at 1:00 p.m. BST (8:00 a.m. EDT).
Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received from the FDA Fast Track Designation for the treatment of Dravet syndrome and Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc
(Today) +44 20 3727 1000
Justin Gover, CEO
+44 1980 557000
Stephen Schultz, VP Investor Relations
+ 1 401 500 6570 or + 1 917 280 2424
FTI Consulting
Ben Atwell / Simon Conway / John Dineen (European media enquiries)
+ 44 20 3727 1000
Robert Stanislaro (US media enquiries)
+1 212 850 5657
Trout Group, LLC (US investor relations)
Todd James / Chad Rubin
+1 646 378 2900
Peel Hunt LLP (UK Nominated Adviser and Broker)
James Steel / Oliver Jackson
+44 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORQKLFLZDFXBBL
1 Year Gw Pharmaceuticals Chart |
1 Month Gw Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions